The role of molecular imaging in modern drug development

Drug Discovery Today

Volumn 19, Issue 7, 2014, Pages 936-948

  Cunha, Lídia ^a   Szigeti, Krisztián ^b   Mathé, Domokos ^c   Metello, Luís F ^a,d  

^a POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c CROmed Ltd   (Hungary)

^d IsoPor   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ANTINEOPLASTIC AGENT; PROTEIN BINDING;

ANIMAL MODEL; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COST; DRUG DEVELOPMENT; DRUG MARKETING; DRUG SAFETY; FLUORESCENCE IMAGING; HUMAN; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCESS OPTIMIZATION; PRODUCTIVITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALIDATION PROCESS; ANIMAL; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROCEDURES; SCINTISCANNING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; MOLECULAR IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84903748665     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.01.003     Document Type: Review

References (86)

1. K.I. Kaitin, and J.A. DiMasi Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009 Clin. Pharmacol. Ther. 89 2011 183 188
2. J.A. DiMasi, and H.G. Grabowski The cost of biopharmaceutical R&D: is biotech different? Manage. Decis. Econ. 28 2007 469 479
3. P. Preziosi Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? Nat. Rev. Drug Discov. 3 2004 521 526 (Pubitemid 38807534)
4. N. Beckmann et al. In vivo mouse imaging and spectroscopy in drug discovery NMR Biomed. 20 2007 154 185 (Pubitemid 46824526)
5. X. Qiu, and S.S. Abdel-Meguid Protein crystallography in structure-based drug design A. Makriyannis, D. Biegel, Drug Discovery Strategies and Methods 2004 Marcel Dekker 1 22
6. M. Pudipeddi et al. Integrated drug product development - from lead candidate selection to life-cycle management C.G. Smith, J.T. O'Donnell, The Process of New Drug Discovery and Development 2006 Informa Healthcare USA 15 54
7. J.S. Fowler et al. PET and drug research and development J. Nucl. Med. 40 1999 1154 1163 (Pubitemid 29315508)
8. M. Rudin, and R. Weissleder Molecular imaging in drug discovery and development Nat. Rev. Drug Discov. 2 2003 123 131 (Pubitemid 37361644)
9. J.H. Kang, and J.K. Chung Molecular-genetic imaging based on reporter gene expression J. Nucl. Med. 49 Suppl. 2 2008 164 179
10. Y. Waerzeggers et al. Multimodality imaging: overview of imaging techniques (CT, MRI, PET, optical imaging) and impact of multimodality imaging on drug development P.H. Elsinga, Trends on the Role of PET in Drug Development 2012 World Scientific 319 382
11. E.H. Ohlstein et al. Drug discovery in the next millennium Annu. Rev. Pharmacol. Toxicol. 40 2000 177 191 (Pubitemid 30340678)
12. J.K. Willmann et al. Molecular imaging in drug development Nat. Rev. Drug Discov. 7 2008 591 607 (Pubitemid 351927724)
13. B.L. Franc et al. Small-animal SPECT and SPECT/CT: important tools for preclinical investigation J. Nucl. Med. 49 2008 1651 1663
14. J.A. DiMasi The value of improving the productivity of the drug development process: faster times and better decisions Pharmacoeconomics 20 Suppl. 3 2002 1 10
15. R.S. Uppoor et al. The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs Clin. Pharmacol. Ther. 84 2008 69 74 (Pubitemid 351861484)
16. P.M. Matthews et al. Positron emission tomography molecular imaging for drug development Br. J. Clin. Pharmacol. 73 2012 175 186
17. E. Ashton Can medical image analysis change the economics of drug development? Pharm. Discov. 2005 Available at: http://www.spectroscopyonline. com/spectroscopy/article/articleDetail.jsp?id=180274&sk=&date= &pageID=3
18. FDA The Center for Drug Evaluation and Research Handbook 1998 Available at: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM198415.pdf (accessed January 2014)
19. X. Zhang et al. Application of microPET imaging approaches in the study of pediatric anesthetic-induced neuronal toxicity J. Appl. Toxicol. 33 2013 861 868
20. S. Kummar et al. Compressing drug development timelines in oncology using phase '0' trials Nat. Rev. Cancer 7 2007 131 139 (Pubitemid 46160988)
21. S. Marchetti, and J.H. Schellens The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials Br. J. Cancer 97 2007 577 581 (Pubitemid 47339894)
22. N. Rick Clinical trials Drugs: From Discovery to Approval 2009 Wiley-Blackwell 176 207
23. L.M. McShane et al. Effective incorporation of biomarkers into Phase II trials Clin. Cancer Res. 15 2009 1898 1905
24. M.D. Garrett et al. The contemporary drug development process: advances and challenges in preclinical and clinical development Prog. Cell Cycle Res. 5 2003 145 158
25. D.C. Anderson, and K. Kodukula Biomarkers in pharmacology and drug discovery Biochem. Pharmacol. 2013 10.1016/j.bcp.2013.08.026
26. W.S. Richter Imaging biomarkers as surrogate endpoints for drug development Eur. J. Nucl. Med. Mol. Imaging 33 Suppl. 1 2006 6 10
27. J. Woodcock, and R. Woosley The FDA critical path initiative and its influence on new drug development Annu. Rev. Med. 59 2008 1 12 (Pubitemid 351287920)
28. L.J. Lesko, and A.J. Atkinson Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies Annu. Rev. Pharmacol. Toxicol. 41 2001 347 366 (Pubitemid 32390116)
29. L.W. Goldman Principles of CT: radiation dose and image quality J. Nucl. Med. Technol. 35 2007 213 225 (quiz 226-218) (Pubitemid 350232322)
30. O.S. Tehrani, and A.F. Shields PET imaging of proliferation with pyrimidines J. Nucl. Med. 54 2013 903 912
31. 18FFLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment Eur. J. Cancer 48 2012 416 424
32. J.R. Allport, and R. Weissleder In vivo imaging of gene and cell therapies Exp. Hematol. 29 2001 1237 1246 (Pubitemid 33033300)
33. M.S. Berridge et al. Imaging studies of biodistribution and kinetics in drug development Drug Dev. Res. 59 2003 208 226 (Pubitemid 36899890)
34. G.C. Kagadis et al. In vivo small animal imaging: current status and future prospects Med. Phys. 37 2010 6421 6442
35. R.P. Maguire Molecular imaging biomarkers as a tool in development of novel medicines P.H. Elsinga, Trends on the Role of PET in Drug Development 2012 World Scientific 33 48
36. R.D. Hichwa, and J.R. Halama Principles of PET and PET/CT imaging R.E. Henkin, Nuclear Medicine vol. 1 2006 Elsevier 257 270
37. A. Rahmim, and H. Zaidi PET versus SPECT: strengths, limitations and challenges Nucl. Med. Commun. 29 2008 193 207 (Pubitemid 351499295)
38. B. Andree et al. Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1 A receptors in the human brain Psychopharmacology (Berl.) 167 2003 37 45 (Pubitemid 36535290)
39. M. Keller et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder Biol. Psychiatry 59 2006 216 223 (Pubitemid 43208967)
40. P. Herrero et al. Assessment of myocardial blood flow using 15 O-water and 1-11 C-acetate in rats with small-animal PET J. Nucl. Med. 47 2006 477 485 (Pubitemid 46768490)
41. S. Kapur Neuroimaging and drug development: an algorithm for decision making J. Clin. Pharmacol. Suppl. 2001 64 71
42. 11C-clozapine to frontal cortex and striatum in drug-free schizophrenics and healthy controls studied by positron emission tomography Acta Radiol. Suppl. 376 1991 153 154
43. A.L. Nordstrom et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients Am. J. Psychiatry 152 1995 1444 1449
44. P.D. Acton et al. Occupancy of dopamine D2 receptors in the mouse brain measured using ultra-high-resolution single-photon emission tomography and 123 IBF Eur. J. Nucl. Med. Mol. Imaging 29 2002 1507 1515 (Pubitemid 35232055)
45. P.H. Elsinga et al. PET tracers for imaging of the dopaminergic system Curr. Med. Chem. 13 2006 2139 2153 (Pubitemid 44132606)
46. L. Farde et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects Arch. Gen. Psychiatry 49 1992 538 544
47. S.R. Meikle et al. Small animal SPECT and its place in the matrix of molecular imaging technologies Phys. Med. Biol. 50 2005 45 61
48. D.L. Bailey, and K.P. Willowson An evidence-based review of quantitative SPECT imaging and potential clinical applications J. Nucl. Med. 54 2013 83 89
49. S.M. Moerlein Radiopharmaceuticals for positron emission tomography R.J. Kowalsky, S.W. Falen, Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine 2004 American Pharmacists Association 337 339
50. L. Fass Imaging and cancer: a review Mol. Oncol. 2 2008 115 152
51. W.A. Kalender et al. X-ray and X-ray CT F. Kiessling, B.J. Pichler, Small Animal Imaging 2011 Springer-Verlag 125 139
52. P. Therasse et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J. Natl. Cancer Inst 92 2000 205 216
53. N.J. Shah et al. Advances in multimodal neuroimaging: hybrid MR-PET and MR-PET-EEG at 3T and 9.4T J. Magn. Reson. 229 2013 101 115
54. W. Koba et al. Imaging devices for use in small animals Sem. Nucl. Med. 41 2011 151 165
55. A. Leroy-Willig, and G. Geldwerth-Feniger Nuclear magnetic resonance imaging and spectroscopy V. Ntziachristos, Textbook of In Vivo Imaging in Vertebrates 2007 Jonh Wiley & Sons 1 56
56. J.P. O'Connor et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents Br. J. Cancer 96 2007 189 195 (Pubitemid 46160619)
57. W.C. Eckelman The use of positron emission tomography in drug discovery and development D.L. Bailey, Positron Emission Tomography: Basic Sciences 2005 Springer 327 341
58. C. Bremer et al. Optical-based molecular imaging: contrast agents and potential medical applications Eur. Radiol. 13 2003 231 243 (Pubitemid 36798598)
59. E.R. McVeigh Emerging imaging techniques Circ. Res. 98 2006 879 886
60. T.F. Massoud, and S.S. Gambhir Molecular imaging in living subjects: seeing fundamental biological processes in a new light Genes Dev. 17 2003 545 580 (Pubitemid 36307540)
61. V. Ntziachristos Tumor imaging V. Ntziachristos, Textbook of In Vivo Imaging in Vertebrates 2007 John Wiley & Sons 277 309
62. J. Comley In vivo preclinical imaging: an essential tool in translational research Drug Discov. World Summer 11 2011 58 71
63. E.D. Agdeppa, and M.E. Spilker A review of imaging agent development AAPS J. 11 2009 286 299
64. AIPES State-of-the-art Nuclear Medicine: SPECT and SPECT/CT imaging - an introduction to mainstay diagnostic testing in non-invasive medicine White Paper 2012 Available at: http://www.aipes-eeig.org/white-paper-spect-spect-ct.html (accessed January 2014)
65. A. Kristian, and O. Alstrup Small animal imaging for accelerating drug development, and comparison to other techniques P.H. Elsinga, Trends on the Role of PET in Drug Development 2012 World Scientific 219 239
66. M. Rudin et al. Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods Mol. Imaging Biol. 7 2005 5 13 (Pubitemid 41348870)
67. J.K. Willmann et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo Radiology 248 2008 936 944
68. K.A. Kurdziel et al. Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18 F-paclitaxel in nonhuman primates J. Nucl. Med. 44 2003 1330 1339 (Pubitemid 39655194)
69. O. Gefvert et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia Psychopharmacology (Berl.) 135 1998 119 126 (Pubitemid 28055494)
70. P. Stenkrona et al. 5-HTT and 5-HT1 A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects Eur. Neuropsychopharmacol. 23 2013 1190 1198
71. A.D. Van den Abbeele The lessons of GIST - PET and PET/CT: a new paradigm for imaging Oncologist 13 Suppl. 2 2008 8 13
72. B. Tavitian et al. In vivo radiotracer imaging V. Ntziachristos, Textbook of In Vivo Imaging in Vertebrates 2007 John Wiley & Sons 103 147
73. J.P. Holland et al. Standardized methods for the production of high specific-activity zirconium-89 Nucl. Med. Biol. 36 2009 729 739
74. R.J. Nickles et al. Technetium-94 m-teboroxime: synthesis, dosimetry and initial PET imaging studies J. Nucl. Med. 34 1993 1058 1066 (Pubitemid 23191319)
75. 2 targets Appl. Radiat. Isotopes 52 2000 181 184
76. C.L. Yasuda et al. The effect of topiramate on cognitive fMRI Epilepsy Res. 105 2013 250 255
77. C.F. Muccio et al. Heat-stroke in an epileptic patient treated by topiramate: follow-up by magnetic resonance imaging including diffusion-weighted imaging with apparent diffusion coefficient measure Clin. Neurol. Neurosurg. 115 2013 1558 1560
78. J.P. Szaflarski, and J.B. Allendorfer Topiramate and its effect on fMRI of language in patients with right or left temporal lobe epilepsy Epilepsy Behav. 24 2012 74 80
79. K.K. Roggin, and M.C. Posner Modern treatment of gastric gastrointestinal stromal tumors World J. Gastroenterol. 18 2012 6720 6728
80. P. Malle et al. FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours Wien Med. Wochenschr. 162 2012 423 429
81. D. Scheller et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease Exp. Neurol. 203 2007 415 422 (Pubitemid 46151765)
82. J.L. Glade Bender et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group Phase I consortium report J. Clin. Oncol. 31 2013 3034 3043
83. F.G. Blankenberg et al. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study Transl. Oncol. 3 2010 56 64
84. E.A. Punnoose et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a Phase II clinical trial of pertuzumab and erlotinib Clin. Cancer Res. 18 2012 2391 2401
85. I. Vaneycken et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer FASEB J. 25 2011 2433 2446
86. L.F.M. Van Zupten Introduction L.F.M. Van Zupten, Principles of Laboratory Animal Science 2001 Elsevier 1 10